Jim Simons Biotechnology

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
NVO Novo Nordisk A S	$197B	$975 Million 1.54% of portfolio	8,189,315	Q3 2024 Reduced 10.65%
UTHR United Therapeutics Corp	$16.4B	$772 Million 1.22% of portfolio	2,155,392	Q3 2024 Reduced 0.89%
VRTX Vertex Pharmaceuticals Inc	$105B	$759 Million 1.2% of portfolio	1,631,493	Q3 2024 Added 4.16%
EXEL Exelixis, Inc.	$10.9B	$399 Million 0.63% of portfolio	15,359,916	Q3 2024 Added 1.3%
CORT Corcept Therapeutics Inc	$5.59B	$301 Million 0.48% of portfolio	6,509,002	Q3 2024 Reduced 5.84%
INCY Incyte Corp	$15.6B	$297 Million 0.47% of portfolio	4,499,540	Q3 2024 Reduced 13.77%
REGN Regeneron Pharmaceuticals, Inc.	$76.6B	$222 Million 0.35% of portfolio	211,423	Q3 2024 Added 14.18%
JAZZ Jazz Pharmaceuticals PLC	$7.76B	$117 Million 0.19% of portfolio	1,049,974	Q3 2024 Added 2.35%
INVA Innoviva, Inc.	$1.24B	$83.6 Million 0.13% of portfolio	4,329,907	Q3 2024 Added 0.09%
ADMA Adma Biologics, Inc.	$3.42B	$73.3 Million 0.12% of portfolio	3,667,196	Q3 2024 Added 42.02%
CPRX Catalyst Pharmaceuticals, Inc.	$2.22B	$50.2 Million 0.08% of portfolio	2,526,016	Q3 2024 Added 16.1%
GMAB Genmab A/S	$13.5B	$43.6 Million 0.07% of portfolio	1,786,428	Q3 2024 Added 22.15%
MRVI Maravai Lifesciences Holdings, Inc.	$701M	$34.4 Million 0.05% of portfolio	4,138,475	Q3 2024 Added 6.62%
BMRN Biomarin Pharmaceutical Inc	$12.4B	$29.4 Million 0.05% of portfolio	418,871	Q3 2024 Added 260.47%
SRPT Sarepta Therapeutics, Inc.	$10.7B	$28.8 Million 0.05% of portfolio	230,478	Q3 2024 Reduced 34.52%
TVTX Travere Therapeutics, Inc.	$1.1B	$26.2 Million 0.04% of portfolio	1,875,014	Q3 2024 Reduced 14.92%
NVAX Novavax Inc	$666M	$26.1 Million 0.04% of portfolio	2,064,783	Q3 2024 Added 85.99%
MRNA Moderna, Inc.	$15.8B	$20.7 Million 0.03% of portfolio	310,300	Q3 2024 Added 261.23%
VCYT Veracyte, Inc.	$2.95B	$20.2 Million 0.03% of portfolio	594,300	Q3 2024 Added 41.23%
PTCT Ptc Therapeutics, Inc.	$3.24B	$20 Million 0.03% of portfolio	538,200	Q3 2024 Reduced 34.21%
HRMY Harmony Biosciences Holdings, Inc.	$2.02B	$19.7 Million 0.03% of portfolio	492,600	Q3 2024 Reduced 17.32%
VNDA Vanda Pharmaceuticals Inc.	$273M	$18.8 Million 0.03% of portfolio	4,011,522	Q3 2024 Reduced 2.49%
BPMC Blueprint Medicines Corp	$5.4B	$16.1 Million 0.03% of portfolio	174,500	Q3 2024 Added 58.06%
HALO Halozyme Therapeutics, Inc.	$6.62B	$14.6 Million 0.02% of portfolio	255,280	Q3 2024 Reduced 32.39%
CYTK Cytokinetics Inc	$4.57B	$12.9 Million 0.02% of portfolio	244,367	Q3 2024 Reduced 48.11%
VKTX Viking Therapeutics, Inc.	$3.25B	$11.7 Million 0.02% of portfolio	184,100	Q3 2024 Added 15.5%
APLS Apellis Pharmaceuticals, Inc.	$3.66B	$10.7 Million 0.02% of portfolio	372,331	Q3 2024 New
RARE Ultragenyx Pharmaceutical Inc.	$3.06B	$10.1 Million 0.02% of portfolio	182,100	Q3 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.34B	$9.44 Million 0.01% of portfolio	44,497	Q3 2024 New
MDXG Mimedx Group, Inc.	$1.04B	$9.01 Million 0.01% of portfolio	1,524,230	Q3 2024 Reduced 2.95%
VIR Vir Biotechnology, Inc.	$979M	$8.86 Million 0.01% of portfolio	1,182,300	Q3 2024 Reduced 11.09%
IMCR Immunocore Holdings PLC	$1.26B	$8.6 Million 0.01% of portfolio	276,200	Q3 2024 Reduced 57.31%
GLPG Galapagos Nv	$1.79B	$8.4 Million 0.01% of portfolio	291,679	Q3 2024 Added 7.71%
FOLD Amicus Therapeutics, Inc.	$2.75B	$8.22 Million 0.01% of portfolio	769,300	Q3 2024 Added 21.72%
ABCL Ab Cellera Biologics Inc.	$841M	$7.63 Million 0.01% of portfolio	2,946,703	Q3 2024 Added 70.47%
IONS Ionis Pharmaceuticals Inc	$5.19B	$7.63 Million 0.01% of portfolio	190,514	Q3 2024 Reduced 23.65%
RNA Avidity Biosciences, Inc.	$1.63B	$6.52 Million 0.01% of portfolio	141,900	Q3 2024 Reduced 62.4%
PTGX Protagonist Therapeutics, Inc	$1.93B	$6.48 Million 0.01% of portfolio	144,167	Q3 2024 Reduced 51.54%
ACAD Acadia Pharmaceuticals Inc	$2.76B	$6.21 Million 0.01% of portfolio	403,200	Q3 2024 Reduced 15.29%
BCYC Bicycle Therapeutics PLC	$436M	$6.18 Million 0.01% of portfolio	272,600	Q3 2024 Reduced 16.59%
NRIX Nurix Therapeutics, Inc.	$923M	$5.53 Million 0.01% of portfolio	246,400	Q3 2024 Reduced 23.95%
ITOS I Teos Therapeutics, Inc.	$266M	$5.48 Million 0.01% of portfolio	536,400	Q3 2024 Reduced 4.15%
ENTA Enanta Pharmaceuticals Inc	$126M	$5.44 Million 0.01% of portfolio	524,900	Q3 2024 Added 2.74%
IDYA Ideaya Biosciences, Inc.	$1.22B	$5.4 Million 0.01% of portfolio	170,365	Q3 2024 Added 55.83%
MREO Mereo Biopharma Group PLC	$476M	$5.37 Million 0.01% of portfolio	1,305,371	Q3 2024 Reduced 25.92%
IMVT Immunovant, Inc.	$3.55B	$5.2 Million 0.01% of portfolio	189,000	Q3 2024 Reduced 51.3%
AKBA Akebia Therapeutics, Inc.	$338M	$4.91 Million 0.01% of portfolio	3,717,800	Q3 2024 Reduced 5.03%
RLAY Relay Therapeutics, Inc.	$509M	$4.75 Million 0.01% of portfolio	671,095	Q3 2024 Reduced 26.18%
CGEM Cullinan Oncology, Inc.	$560M	$4.72 Million 0.01% of portfolio	281,800	Q3 2024 Reduced 33.18%
XERS Xeris Biopharma Holdings, Inc.	$472M	$4.56 Million 0.01% of portfolio	1,598,720	Q3 2024 Added 18.28%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account